Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 18/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5101962 | 0.89 | BRAF (1.00) | BRAFKDRCYP3A4 | |
| SCHEMBL4819011 | 0.85 | BRAF (1.00) | BRAFKDRCYP3A4 | |
| SCHEMBL14033895 | 0.83 | BRAF (1.00) | BRAFKDRCYP3A4 | |
| SCHEMBL5108291 | 0.83 | BRAF (1.00) | BRAFKDRCYP3A4 | |
| SCHEMBL14033746 | 0.83 | BRAF (0.76) | BRAFKDRCYP3A4 | |
| SCHEMBL233442 | 0.83 | KDR (1.00) | BRAFKDRCYP3A4 | |
| SCHEMBL4697938 | 0.82 | BRAF (1.00) | BRAFKDRCYP3A4 | |
| SCHEMBL5098603 | 0.82 | BRAF (1.00) | BRAFKDRCYP3A4 | |
| SCHEMBL1694775 | 0.82 | KDR (0.97) | BRAFKDRCYP3A4 | |
| SCHEMBL4697148 | 0.82 | BRAF (1.00) | BRAFKDRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255184-A1 | Thienopyridine B-Raf Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-10-16 | — | — | US | claimed |
| US-20080255184-A1 | Thienopyridine B-Raf Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-10-16 | — | — | US | disclosed |
| US-20080255184-A1 | Thienopyridine B-Raf Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-10-16 | — | — | US | disclosed |
| WO-2007056625-A2 | THIENOPYRIDINE B-RAF KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255184-A1 | Thienopyridine B-Raf Kinase Inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885KDR 423/4885CYP3A4 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.